Calafiore Antonio M, de Paulis Ruggero, Iesu Severino, Paparella Domenico, Angelini Gianni, Scognamiglio Mattia, Centofanti Paolo, Nicolardi Salvatore, Chivasso Pierpaolo, Canosa Carlo, Zaccaria Salvatore, de Martino Luigi, Magnano Diego, Mastrototaro Giuseppe, Di Mauro Michele
Department of Cardiovascular Sciences, Gemelli Molise, Campobasso, Italy.
Division of Cardiac Surgery, European Hospital, Rome, Italy.
J Card Surg. 2022 Dec;37(12):4982-4990. doi: 10.1111/jocs.17207. Epub 2022 Nov 20.
Deep hypothermic circulatory arrest (DHCA) at ≤20°C for aortic arch surgery has been widely used for decades, with or without cerebral perfusion (CP), antegrade (antegrade cerebral perfusion [ACP]), or retrograde. In recent years nadir temperature progressively increased to 26°C-28°C (moderately hypothermic circulatory arrest [MHCA]), adding ACP. Aim of this multicentric study is to evaluate early results of aortic arch surgery and if DHCA with 10 min of cold reperfusion at the same nadir temperature of the CA before rewarming (delayed rewarming [DR]) can provide a neuroprotection and a lower body protection similar to that provided by MHCA + ACP.
A total of 210 patients were included in the study. DHCA + DR was used in 59 patients and MHCA + ACP in 151. Primary endpoints were death, neurologic event (NE), temporary (TNE), or permanent (permanent neurologic deficit [PND]), and need of renal replacement therapy (RRT).
Operative mortality occurred in 14 patients (6.7%), NEs in 17 (8.1%), and PNDs in 10 (4.8%). A total of 23 patients (10.9%) needed RRT. Death + PND occurred in 21 patients (10%) and composite endpoint in 35 (19.2%). Intergroup weighed logistic regression analysis showed similar prevalence of deaths, NDs, and death + PND, but need of RRT (odds ratio [OR]: 7.39, confidence interval [CI]: 1.37-79.1) and composite endpoint (OR: 8.97, CI: 1.95-35.3) were significantly lower in DHCA + DR group compared with MHCA + ACP group.
The results of our study demonstrate that DHCA + DR has the same prevalence of operative mortality, NE and association of death+PND than MHCA + ACP. However, the data suggests that DHCA + DR when compared with MHCA + ACP provides better renal protection and reduced prevalence of composite endpoint.
几十年来,主动脉弓手术中≤20°C的深低温停循环(DHCA)已被广泛应用,无论是否进行脑灌注(CP),包括顺行(顺行性脑灌注[ACP])或逆行性脑灌注。近年来,最低体温逐渐升至26°C - 28°C(中度低温停循环[MHCA]),并增加了ACP。这项多中心研究的目的是评估主动脉弓手术的早期结果,以及在复温前与停循环时相同最低体温下进行10分钟冷再灌注的DHCA(延迟复温[DR])是否能提供与MHCA + ACP相似的神经保护和身体下部保护。
共有210例患者纳入本研究。59例患者采用DHCA + DR,151例患者采用MHCA + ACP。主要终点为死亡、神经事件(NE),包括暂时性(TNE)或永久性(永久性神经功能缺损[PND]),以及肾脏替代治疗(RRT)的需求。
14例患者(6.7%)发生手术死亡,17例(8.1%)发生神经事件,10例(4.8%)发生永久性神经功能缺损。共有23例患者(10.9%)需要进行肾脏替代治疗。21例患者(10%)发生死亡 + PND,35例(19.2%)发生复合终点事件。组间加权逻辑回归分析显示,死亡、神经功能缺损和死亡 + PND的发生率相似,但与MHCA + ACP组相比,DHCA + DR组的肾脏替代治疗需求(比值比[OR]:7.39,置信区间[CI]:1.37 - 79.1)和复合终点事件(OR:8.97,CI:1.95 - 35.3)显著更低。
我们的研究结果表明,DHCA + DR与MHCA + ACP相比,手术死亡率、神经事件以及死亡 + PND的发生率相同。然而,数据表明,与MHCA + ACP相比,DHCA + DR能提供更好的肾脏保护,并降低复合终点事件的发生率。